Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate whether saxagliptin is non-inferior to basal-bolus insulin therapy for glycemic control in patients with controlled type 2 diabetes mellitus (T2DM) admitted to hospital with non-critical illnesses. Research design and methods: This was an open-label, randomized controlled clinical trial. Patients received either saxagliptin or basal-bolus insulin, both with correctional insulin doses. The main study outcome was the mean daily blood glucose (BG) after the first day of randomization. Results: Of 66 patients completing the study, 33 (age 69±10 years, 40% men) were randomized to saxagliptin and 33 (age 67±10 years, 52% men) to basal-bolus insulin therapy. The mean daily BG was 149.8±22.0 mg/dL in the saxagliptin group and 146.9±30.5 mg/dL in the insulin group (p=0.59). With an observed group difference of 2.9 mg/dL and an a priori margin of 20 mg/dL, inferiority of saxagliptin was rejected in favor of non-inferiority (p=0.007). There was no significant difference in the percentage of high or low BG values. The insulin group received a higher number of insulin injections (2.3±1.7/day vs 1.2±1.9/day; p<0.001) as well as a higher daily insulin dose (13.3±12.9 units/day vs 2.4±3.3 units/day; p<0.001) than did the saxagliptin group. Continuous BG monitoring showed that glycemic variability was lower in the saxagliptin group as compared to the insulin group. Patient satisfaction scores were similar in the two groups. Conclusions: We conclude that saxagliptin use is non-inferior to basal-bolus insulin in non-critically ill hospitalized patients with T2DM controlled on 0–2 oral agents without insulin. Saxagliptin use may decrease glycemic variability in these patients. Trial registration number: NCT02182895.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A few randomized trials demonstrated the safety and efficacy of DPP-4i in specific groups of hospitalized people with diabetes (91-93).”
From 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026 (2026) · cites this paper as [93]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although some RCTs have shown similar glycemic control and lower hypoglycemia with the use of insulin analogs1308 in low-resource settings, the use of NPH may result in similar glycemic control, with minimally increased hypoglycemia,1347,1348 albeit with higher insulin dose and injections per day.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1348]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes
Umpierrez, G. E., Isaacs, S. D., Bazargan, N., You, X., Thaler, L. M., & Kitabchi, A. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8341 · Cited by 2,195
Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care · doi:10.2337/dc09-9029 · Cited by 1,444
Umpierrez, G. E., Hellman, R., Korytkowski, M. T., Kosiborod, M., Maynard, G. A., Montori, V. M., Seley, J. J., & Van den Berghe, G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2098 · Cited by 1,126
Umpierrez, G. E., Smiley, D., Jacobs, S., Peng, L., Temponi, A., Mulligan, P., Umpierrez, D., Newton, C., Olson, D., & Rizzo, M. (2011) · Diabetes Care · doi:10.2337/dc10-1407 · Cited by 720
Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke
Williams, L. S., Rotich, J., Qi, R., Fineberg, N., Espay, A., Bruno, A., Fineberg, S. E., & Tierney, W. R. (2002) · Neurology · doi:10.1212/wnl.59.1.67 · Cited by 476
Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward
Turchin, A., Matheny, M. E., Shubina, M., Scanlon, J. V., Greenwood, B., & Pendergrass, M. L. (2009) · Diabetes Care · doi:10.2337/dc08-2127 · Cited by 453
Hill, N. R., Oliver, N. S., Choudhary, P., Levy, J. C., Hindmarsh, P., & Matthews, D. R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0247 · Cited by 362
Garg, R., Chaudhuri, A., Munschauer, F., & Dandona, P. (2006) · Stroke · doi:10.1161/01.str.0000195175.29487.30 · Cited by 241
Self-citationMendez, C. E., Mok, K.-T., Ata, A., Tanenberg, R. J., Calles-Escandon, J., & Umpierrez, G. E. (2013) · Diabetes Care · doi:10.2337/dc12-2430 · Cited by 209
Glycemic Control in Non-Critically Ill Hospitalized Patients: A Systematic Review and Meta-Analysis
Murad, M. H., Coburn, J. A., Coto-Yglesias, F., Dzyubak, S., Hazem, A., Lane, M. A., Prokop, L. J., & Montori, V. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2100 · Cited by 192
Research works printed but not linked: 1
- 10.1210/jc.87.3.978 · DOI · Paper page
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationManagement of diabetes and hyperglycaemia in the hospital
Pasquel, F. J., Lansang, M. C., Dhatariya, K., & Umpierrez, G. E. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30381-8 · Cited by 329
Korytkowski, M. T., Muniyappa, R., Antinori-Lent, K., Donihi, A. C., Drincic, A. T., Hirsch, I. B., Luger, A., McDonnell, M. E., Murad, M. H., Nielsen, C., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac278 · Cited by 315
“Benefits and harms The systematic review identified 5 RCTs that compared the effects of a noninsulin agent without scheduled insulin in comparison to an insulin-only approach (11, 105-109).”
Background15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s015 · Cited by 216
14. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s014 · Cited by 178
Metadata
- Authors
- Garg, R., Schuman, B., Hurwitz, S., Metzger, C., & Bhandari, S.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Garg, Rajesh
- ORCID
- Garg, Rajesh
- Venue
- BMJ Open Diabetes Research & Care
- Publisher
- BMJ
- Published
- 2017-03
- Volume
- 5
- Issue
- 1
- Pages
- e000394
- ISSN
- 2052-4897 (ISSN-L)
- PMC
- PMC5372055
- OpenAlex
- W2599515436
- Cited by
- 79
- References
- 24
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 8 · 2023: 8 · 2022: 11 · 2021: 12 · 2020: 12 · 2019: 11 · 2018: 10 · 2017: 3
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open Diabetes Research & Care (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- saxagliptin, multiple daily insulin injections, type 2 diabetes, glycemic control, hospitalized patients, non-critically ill patients, glycemic variability, continuous glucose monitoring, non-inferiority, insulin dose reduction, patient satisfaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. https://app.cochat.ai/papers/10.1136/bmjdrc-2017-000394
- The paper
- Garg, R., Schuman, B., Hurwitz, S., Metzger, C., & Bhandari, S. (2017). Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. BMJ Open Diabetes Research & Care. https://doi.org/10.1136/bmjdrc-2017-000394
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

